Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service mechanical circulatory support cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (146 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 6 | 1,254 | 46% |
| 2020 | 6 | 1,211 | 48% |
| 2021 | 6 | 1,233 | 51% |
| 2022 | 5 | 1,177 | 53% |
| 2023 | 6 | 1,116 | 55% |
| 2024 | 4 | 1,076 | 57% |
| 2025 from claims | – | 1,056 969–1,118 | 58% |
| 2026 forecast | – | 1,066 938–1,230 | 58% |
| 2027 forecast | – | 1,071 915–1,276 | 59% |
| 2028 forecast | – | 1,076 897–1,317 | 59% |
| 2029 forecast | – | 1,080 882–1,355 | 60% |
| 2030 forecast | – | 1,085 869–1,390 | 60% |
Percutaneous ventricular assist and intra-aortic balloon pump. Professional codes (what the surgeon bills): CPT 33990, 33991, 33995, 33967, 33970; the hospital bills MS-DRG 268, 269.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New York; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 98% inpatient hospital, 2% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 2 | 838−4.5%/yr | −4.5%/yr | 0.6 | 0% | 950 in 2030+2%/yr |
| Massachusetts | 3 | 596−1.7%/yr | −1.7%/yr | 0.6 | 0% | 560 in 2030−0.9%/yr |
| New Jersey | 1 | 507+0.1%/yr | +0.1%/yr | 0.5 | 0% | 870 in 2030+9.4%/yr |
| Connecticut | 1 | 152−4.1%/yr | −4.1%/yr | 0.5 | 0% | 40 in 2030−18%/yr |
| New Hampshire | 2 | 133+3.3%/yr | +3.3%/yr | 0.6 | 0% | 120 in 2030−1.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Coronary intervention (PCI) | 245 | 13,378−4.1%/yr | −4.1%/yr | 5.91.3× | 0% | 13,900 in 2030+0.6%/yr |
| Structural heart (TAVR, TEER) | 150 | 4,552+1.5%/yr | +1.5%/yr | 2.11.3× | 0% | 6,000 in 2030+4.7%/yr |
| PFO & septal closure | 2 | 153+0.3%/yr | +0.3%/yr | 0.11.3× | 0% | 150 in 2030+0.1%/yr |
Mechanical circulatory support in every state, and its device makers · Every procedure market in New York · Every state · Compare with Pennsylvania
Enablecv leads with 81% of company spending on these surgeons in 2025, +80 pts on 2024.
In 2025, 2 companies reported engagement with New York’s surgeons worth $22K in consulting, speaking, meals and travel tied to these products, about $5,443 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 48 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
New York’s own discharge file counts every inpatient stay, whatever the payer: 734 heart assist devices stays at 21 hospitals in 2024, against the Medicare-only figures above. The most commercial of the busy ones is STRONG MEMORIAL HOSPITAL (31% commercial): where commercial rates leave the most room for a premium product.
| Hospital | Cases | Medicare | Commercial |
|---|---|---|---|
| NEW YORK-PRESBYTERIAN HOSPITAL NEW YORK | 81 | 53% | 25% |
| MOUNT SINAI HOSPITAL NEW YORK | 73 | 63% | 27% |
| STRONG MEMORIAL HOSPITAL ROCHESTER | 61 | 46% | 31% |
| NYU LANGONE HOSPITALS NEW YORK | 61 | 57% | — |
| ST JOSEPH'S HOSPITAL HEALTH CENTER SYRACUSE | 47 | 60% | — |
| MONTEFIORE MEDICAL CENTER BRONX | 45 | 67% | — |
| ROCHESTER GENERAL HOSPITAL ROCHESTER | 44 | 86% | — |
| NORTH SHORE UNIVERSITY HOSPITAL MANHASSET | 44 | 59% | — |
New York only: MedaRep has no other state’s all-payer file yet. Counted by principal procedure (Heart assist devices: impella, LVAD and similar; balloon pumps are not counted.). Medicare here includes Medicare Advantage. A hospital with 10 or fewer such stays, or a payer share of 10 or fewer, is not shown. Source: New York State Department of Health, SPARCS de-identified inpatient discharges (health.data.ny.gov). The New York State Department of Health makes no representation, warranty or guarantee relating to the data or analyses derived from these data. Accessed 2026-11-11.